Neramexane, developed by Forest Laboratories, targets moderate to severe Alzheimer's disease by inhibiting NMDA receptor activity linked to glutamate toxicity. The Alzheimer's market is substantial, with a growing demand for effective treatments as the global population ages. Given the competitive landscape, which includes established therapies and emerging candidates, successful outcomes from this trial could position Neramexane favorably. However, the market is also characterized by significant scrutiny regarding safety and efficacy, necessitating robust clinical data to support commercialization efforts.